Cancer Genetics and Epigenetics 2017, Vol.5, No.7, 33-38
37
Authors’ contributions
Huijie Jiang conceived and designed the work that led to the submission. Mingyu Zhang and Hailong Xu evaluated images and
analyzed data. Mingyu Zhang and Hao Jiang measured and acquired data. All authors participated in paper writing and approved the
final manuscript.
Acknowledgments
The study was supported by the Key Projects in the National Science & Technology Pillar Program during the Twelfth Five-year Plan
Period (Grant number 2015BAI01B09), the National Natural Science Foundation of China (Grant number 81471736 and 81671760)
and Harbin Special Foundation for the Research of Scientific and Technological Innovation Talents (Grant number 2016RAXYJ063).
Reference
Broos K., Keyaerts M., Lecocq Q., Renmans D., Nguyen T., Escors D., Liston A., Raes G., Breckpot K., and Devoogdt N., 2017, Non-invasive assessment of
murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers, Oncotarget, 8(26): 41932-41946
Chatterjee S., Lesniak W.G., Gabrielson M., Lisok A., Wharram B., Sysa-Shah P., Azad B.B., Pomper M.G., and Nimmagadda S., 2016, A humanized antibody
for imaging immune checkpoint ligand PD-L1 expression in tumors, Oncotarget, 7(9): 10215-10227
PMid:26848870 PMCid:PMC4891115
Duraiswamy J., Kaluza K.M., Freeman G.J., and Couko G., 2013, Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell
rejection function in tumors, Cancer Res., 73(12): 3591-603
PMid:23633484 PMCid:PMC3686913
Fecci P.E., Ochiai H., Mitchell D.A., Grossi P.M., Sweeney A.E., Archer G.E., Cummings T., Allison J.P., Bigner D.D., and Sampson J.H., 2007, Systemic
CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function, Clin Cancer Res,
13(7): 2158-67
PMid:17404100
Gangadhar T.C. and Salama A.K., 2015, Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma
and other tumor types, Onco Targets Ther, 8: 929-37
PMid:25960664 PMCid:PMC4410900
Grauer O.M., Nierkens S., Bennink E., Toonen L.W., Boon L., Wesseling P., Sutmuller R.P., and Adema G.J., 2007, CD4+FoxP3+ regulatory T cells gradually
accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo, Int J Cancer, 121(1): 95-105
PMid:17315190
Grosso J.F., and Jure-Kunkel M.N., 2013, CTLA-4 blockade in tumor models: an overview of preclinical and translational research, Cancer Immunity, 13(1): 5
PMid:23390376 PMCid:PMC3559193
Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., Hanada K., Almeida J.R., Darko S., Douek
D.C., Yang J.C., and Rosenberg S.A., 2014, PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors, Journal of
Clinical Investigation, 124(5): 2246-2259
PMid:24667641 PMCid:PMC4001555
Hettich M., Braun F., Bartholomä M.D., Schirmbeck R., and Niedermann G., 2016, High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1
checkpoint tracers, Theranostics, 6(10): 1629-40
PMid:27446497 PMCid:PMC4955062
Honda T., Egen J.G., Lämmermann T., Kastenmüller W., Torabi-Parizi P., and Germain R.N., 2014, Tuning of antigen sensitivity by T cell receptor-dependent
negative feedback controls T cell effector function in inflamed tissues, Immunity, 40(2): 235-247
PMid:24440150 PMCid:PMC4792276
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den
Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D.,
Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., and Urba W.J., 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N
Engl J Med, 363(8): 711-23
PMid:20525992 PMCid:PMC3549297
Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., and Frohlich M.W.,
2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, The New England Journal of Medicine, 363(5): 411-422
